<DOC>
	<DOCNO>NCT01582230</DOCNO>
	<brief_summary>The purpose study assess efficacy safety vildagliptin 50mg bid add-on therapy improve overall glycemic control patient type 2 diabetes mellitus inadequately control insulin without metformin treatment .</brief_summary>
	<brief_title>Efficacy Safety Vildagliptin 50mg Bid add-on Therapy Insulin With Without Metformin , Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients confirm diagnosis Type2 diabetes mellitus ( T2DM ) standard criterion Cpeptide &gt; 0.6 ng/ml ( &gt; 0.20 nmol/L ) . HbA1c ≥7.5 ≤11 % Visit 1 Treatment stable , twice daily dos ( maximum dose &lt; 1 unit/kg/day ) basal ( longacting , intermediateacting ) insulin alone premixed insulin least 12 week prior Visit 1 . Stable defined ±10 % Visit 1 dose previous 12 week Patients receive metformin must stable dose metformin ( least 1500 mg daily maximally tolerate dose ) least 12 week prior Visit 1 Body Mass Index ( BMI ) ≥20 ≤40 kg/m2 Visit Patients fulfil follow criterion eligible participation study Fasting plasma glucose ( FPG ) ≥240 mg/dl ( 13.3 mmol/L ) Visit 1 Pregnant lactate woman Acute metabolic diabetes complication ketoacidosis hyperosmolar state ( coma ) within past 6 month Current diagnosis congestive heart failure ( NYHA III IV ) . Myocardial infarction ( MI ) within past 6 month Liver disease cirrhosis chronic active hepatitis Other protocol define inclusion/excusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Vildagliptin</keyword>
</DOC>